Wall Street Expecting Delays to Antitrust Clearance for Cephalon/Teva Deal (CEPH) (TEVA)
Tweet
Share
E-mailGet Alerts CEPH Hot Sheet
Join SI Premium – FREE
DealReporter is saying the potential deal between Cephalon (Nasdaq: CEPH) and Teva (Nasdaq: TEVA) may take longer-than-expected to get antitrust clearance as the transaction would include a number of reverse settlements.
Specifically, DealReporter's sources say Cephalon and Teva have been "singled out" due to their "pay-for-delay" practices.
Specifically, DealReporter's sources say Cephalon and Teva have been "singled out" due to their "pay-for-delay" practices.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Magna Holdings makes unsolicited bid for 31% of Yatra Online
- Vireo Growth completes acquisition of C21 Investments
Create E-mail Alert Related Categories
RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
